
Milbank announced that Daniel Rosenthal joined the firm’s Washington, DC office as special counsel in the Global Antitrust and Competition Practice.
Mr. Rosenthal brings to Milbank deep expertise in merger control, government antitrust reviews and the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act). Mr. Rosenthal has over a decade of experience advising clients on complex antitrust investigations by the Department of Justice and Federal Trade Commission, as well as cross-border M&A transactions. His notable representations include Sun Chemical and DIC Corporation on their acquisition of BASF’s Global Pigments Business.
In addition, Mr. Rosenthal regularly advises clients on issues related to the HSR Act, as well as international merger reviews.
“We are thrilled to welcome Dan to the firm and practice,” said Fiona Schaeffer, head of Milbank’s US Antitrust and Competition Practice. “His expertise will be invaluable as we continue to expand and enhance our antitrust bench across the globe and help clients successfully navigate the increasingly complex and challenging merger review environment in the US and internationally.”
“Dan is a seasoned antitrust lawyer and HSR expert who has successfully handled bet-the-company matters,” said Milbank antitrust partner Adam Di Vincenzo, who recently joined the DC office. “His experience and track record are critical to businesses that face intense antitrust scrutiny in an ever-changing enforcement environment.”
“Joining Milbank’s dynamic and expanding Global Antitrust and Competition practice is a special opportunity,” Mr. Rosenthal said. “I am proud to join my new colleagues who are known for their collaboration in delivering commercially-oriented and effective legal strategies and solutions for the most complex issues our clients are facing around the world.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas